NCT06024876View on ClinicalTrials.gov

A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 26, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Beta-Thalassemia
Interventions
BIOLOGICAL

CS-101

Autologous CD34+ hematopoietic stem cell suspension modified by ex vivo base editing technique

Trial Locations (1)

Unknown

The First Affiliated Hospital of Guangxi Medical University, Nanning

Sponsors
All Listed Sponsors
collaborator

First Affiliated Hospital of Guangxi Medical University

OTHER

lead

CorrectSequence Therapeutics Co., Ltd

INDUSTRY